LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients

Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E

(2011) S. Akli et al.   CANCER RESEARCH

Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression

(2011) Hannah Wingate et al.   CELL CYCLE

Low Molecular Weight Cyclin E Overexpression Shortens Mitosis, Leading to Chromosome Missegregation and Centrosome Amplification

(2010) Rozita Bagheri-Yarmand et al.   CANCER RESEARCH

Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors

(2010) S. Akli et al.   CLINICAL CANCER RESEARCH

A novel interaction between HER2/neu and cyclin E in breast cancer

(2010) E A Mittendorf et al.   ONCOGENE

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

(2009) Britta Weigelt et al.   BREAST CANCER RESEARCH AND TREATMENT

Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

(2009) B. T. Hennessy et al.   CANCER RESEARCH

Functional proteomic profiling of AML predicts response and survival

(2008) S. M. Kornblau et al.   BLOOD

Autophagy: A Novel Mechanism of Synergistic Cytotoxicity between Doxorubicin and Roscovitine in a Sarcoma Model

(2008) L. A. Lambert et al.   CANCER RESEARCH

Prognostic Breast Cancer Signature Identified from 3D Culture Model Accurately Predicts Clinical Outcome across Independent Datasets

(2008) Katherine J. Martin et al.   PLoS One